News Search Results
Oct 24, 2025, 08:00 ET Orna Therapeutics Announces Encore Presentation at the American College of Rheumatology Annual Meeting Supporting its in vivo CAR Therapy Approach in Autoimmune Diseases
WATERTOWN, Mass., Oct. 24, 2025 /PRNewswire/ -- Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced
More news about: Orna Therapeutics
Oct 24, 2025, 07:00 ET Origin Agritech Obtains New Licenses for Crop Seed Production and GMO Business Operations
authorization allows Origin to participate in China's rapidly evolving GMO seed sector, positioning the Company to capitalize on the increasing adoption of biotechnology in agriculture. Each specific GMO crop will continue to require individual registration and approval prior to commercialization.
More news about: Origin Agritech Limited
Oct 24, 2025, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 24, 2025, 06:45 ET Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 23, 2025, 19:30 ET HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies, today presented new results from its ongoing Phase 1 study of HCB101, a novel SIRPα-engineered
More news about: HanchorBio Inc.
Oct 23, 2025, 16:58 ET CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment
SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ -- CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today announced the initiation of a randomized, double-blind, vehicle-controlled
More news about: CAGE Bio Inc.
Oct 23, 2025, 16:05 ET INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
(NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat at the upcoming Stephens Biotechnology Virtual Fireside
More news about: INOVIO Pharmaceuticals, Inc.
Oct 23, 2025, 16:05 ET Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
diseases, today announced that it has earned the highest ranking in Science's 2025 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the companies with the best reputations as employers. "It is an incredible
More news about: Insmed Incorporated
Oct 23, 2025, 14:36 ET Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC
Mass., Oct. 23, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to zenocutuzumab-zbco
More news about: Partner Therapeutics, Inc.
Oct 23, 2025, 12:00 ET Czech Breakthrough in Medicine: H₂ Global Group Receives Regulatory Approval for Hydrogen Clinical Study -- New Era in Alzheimer's Therapy Begins
This milestone marks a historic achievement for Czech and European biotechnology, as it represents Europe's first fully approved clinical trial investigating non-invasive hydrogen inhalation as a neuroprotective therapy.
More news about: H2 Global Group
Oct 23, 2025, 11:52 ET Osmolality as a Key to Diagnosing Diabetes Insipidus, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 23, 2025, 11:00 ET Medical Device Market Surges to USD 750 Billion by 2033, Propelled by 5.5% CAGR - Verified Market Reports®
Device Market The next generation of medical devices is defined by cross-domain innovation—merging biotechnology, materials engineering, and artificial intelligence. Smart implants capable of wireless communication are now used for continuous patient monitoring,
More news about: Verified Market Reports
Oct 23, 2025, 10:29 ET Protai Showcases Breakthroughs in Structural-Proteomics & AI Driven Drug Discovery at October Global Conferences
classical drug discovery methods." About Protai: Protai is a structural-proteomics and AI-driven biotechnology company pioneering Proteomics-aware-AI for drug discovery. Its AIMS™ platform integrates mass-spectrometry-based structural proteomics,
More news about: Protai
Oct 23, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
here for information about joining the class action] Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible
More news about: Pomerantz LLP
Oct 23, 2025, 09:20 ET Antelope Surgical Solutions Selected to Present at the 2025 Mid-Atlantic Capital Conference, Showcasing Technology That Makes Cancer Visible
Antelope Surgical Solutions, a clinical-stage theranostics biotechnology company pioneering the world's first fluorescent radioligand platform that helps physicians see and treat cancer with precision, today announced
More news about: Antelope Surgical Solutions, Inc.
Oct 23, 2025, 08:55 ET Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
clinical trials and product development programs; difficulties or delays in obtaining regulatory approval; competition from other pharmaceutical or biotechnology companies; market volatility affecting our investment portfolio; our ability to realize expected returns from Scilex and other investments; and
More news about: Oramed Pharmaceuticals Inc.
Oct 23, 2025, 08:45 ET Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Spartan Capital Securities Second Annual
More news about: Anixa Biosciences, Inc.
Oct 23, 2025, 08:33 ET BridGene Biosciences to Present Three Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
About BridGene Biosciences BridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat
More news about: BridGene Biosciences
Oct 23, 2025, 08:30 ET Improve Clinical Trial Delivery by Leveraging AI Forecasting Tools, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 23, 2025, 08:30 ET Drug Compendia: Practical Strategies to Bridge Evidence and Payer Coverage, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 23, 2025, 08:00 ET Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity
SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- Vial, a clinical-stage biotechnology company, announced that it is initiating the Phase 1 trial for a novel INHBE (Activin E) siRNA, which is being developed as a potentially best-in-class
More news about: Vial
Oct 23, 2025, 08:00 ET Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
[email protected] About STRM.BIOBased in Cambridge, MA, STRM.BIO is a pre-clinical, venture-backed biotechnology company leveraging extracellular vesicles as a platform to develop and deliver targeted genetic medicines in vivo that are safe for repeat
More news about: Ginkgo Bioworks
Oct 23, 2025, 07:00 ET HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development of
More news about: HanchorBio Inc.
Oct 23, 2025, 06:55 ET Phase Change Materials Market worth $1,639.71 million by 2030 - Exclusive Report by MarketsandMarkets™
cooling loads, and lower energy costs. The rapid expansion of cold chain logistics, especially for pharmaceuticals, vaccines, perishable foods, and biotechnology products, has further accelerated PCM adoption, as these materials ensure stable temperatures during transport and storage while minimizing spoilage
More news about: MarketsandMarkets
Oct 23, 2025, 06:00 ET Swiss Rockets and Squirro Announce Strategic Partnership to Accelerate AI Transformation in Biotechnology
Oct. 23, 2025 /PRNewswire/ -- Swiss Rockets AG, a Basel-based biotechnology incubator and accelerator, and Squirro AG, a leading Swiss enterprise AI company,
More news about: Squirro